News Briefs: May 15, 2023

The Drug Enforcement Administration (DEA) has extended telemedicine flexibilities for controlled medicine prescriptions for six months, according to a temporary rule published in the Federal Register May 10.[1] That means physicians can continue to prescribe controlled substances to patients by telehealth without an initial in-person visit, the same way they did during the COVID-19 public health emergency, until Nov. 11. The rule came down a day before the PHE and many of its waivers ended on May 11. Meanwhile, the DEA continues to work on a permanent rule on telehealth prescriptions for controlled substances. The March 1 proposed version elicited 38,000 comments.

This document is only available to subscribers. Please log in or purchase access.
 


Would you like to read this entire article?

If you already subscribe to this publication, just log in. If not, let us send you an email with a link that will allow you to read the entire article for free. Just complete the following form.

* required field